Biologics / Biotechnology

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biologics / Biotechnology #Business #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Tackling Multi-Drug Resistant Bacteria

Tackling Multi-Drug Resistant Bacteria By Dr Ankit Mahadevia Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such as beta-lactam, tetracyclines… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #Screening #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Raising The Bar On The Biologics Potential

Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More

#Archive

Cancer cells
#Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Metabolomics #Microbiome #Oncology #Orphan drugs #PCR #Regulatory #RNA #Stem cells #Therapeutics

Immuno-Oncology’s Biomarker Dilemma: How to add value in an uncertain development landscape

Immuno-Oncology's Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biologics / Biotechnology #Business #Cell culture #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #In Silico Biology #Lead discovery #Lead optimisation #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Is The Cloud Enabling Bioinformatics to Become the Biology Solutions Domain?

By Dr Paul Denny-Gouldson For many years we have used the term bioinformatics to describe, well, anything outside cheminformatics in the R&D informatics domain. It has been a ‘catch-all’ term to label informatics tools that handle biologically relevant information. But the tools and software that have been labelled as such… Read More

#Archive

Gene therapy
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Regenerative Medicine #Regulatory #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Cell Therapy & Gene Therapy – The emerging fourth pillar of healthcare systems

Cell Therapy & Gene Therapy - The emerging fourth pillar of healthcare systems By Keith Thompson As the CEO of an organisation that deals exclusively in cell therapy and gene therapy, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Antimicrobials #Biologics / Biotechnology #Biomarkers #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Immunology / Virology & Vaccines #Lead discovery #Microbiome #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics

The Human Microbiome – A new frontier in drug discovery

The Human Microbiome - A new frontier in drug discovery By Lee Jones There is a new phenomenon sweeping the globe (or at least sweeping the imagination of people around the globe). It is the human gut microbiome and the role it may play in the future of human health. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #PCR #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Ion Channels – Increasingly Enticing Targets For Drug Discovery

Ion Channels - Increasingly Enticing Targets For Drug Discovery by Dr Douglas Krafte and Deborah Erickson Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease. Pfizer Inc’s… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Ex Vivo vs In Vivo – The challenge of generating meaningful results with traditional cell culture

By Dr James Lim and Dr Fred Aswad While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results. This article discusses current attempts to make results from cell culture systems more biologically relevant which,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #Therapeutics

mRNA Will Revolutionise the Biopharmaceutical Industry

mRNA Will Revolutionise the Biopharmaceutical Industry By Dr Ingmar Hoerr Messenger RNA (mRNA) - the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell's DNA into the proteins essential for maintaining cell function and ensuring an organism’s survival,… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Toxicology

Therapeutic Drug Repurposing, Repositioning and Rescue Part III

Therapeutic Drug Repurposing, Repositioning and Rescue Part III: Market exclusivity using Intellectual Property and regulatory pathways By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned stakeholders. In… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order for their… Read More

#Archive

#Academic #Analytical chemistry #Animal models #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Lead optimisation #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Target validation #Toxicology

The Chinese Biologics Drug Market: Demand and Execution

By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu In the past decade, China's drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical companies to develop, manufacture… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Translational #Translational chemistry

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview

Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview By Dr Stephen Naylor & Judge M. Schonfeld The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Oncology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

Opportunities For Phenotypic Screening In Drug Discovery

Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More

#Archive

#Academic #Analysis #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Oncology #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Cellular Raw Material Collection In Cell Therapy: Critical Determinant of Product Quality

By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. These novel biologics have potential… Read More

#Archive